Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM4 | Q14833 | 19/20 | 0.67 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.67 |
| ▸ | HTR2B | P41595 | 1/20 | 0.67 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.67 |
| ▸ | CCNC | P24863 | 1/20 | 0.48 |
| ▸ | CDK8 | P49336 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2710540 | 0.86 | GRM4 (0.77) | GRM4KCNH2HTR2BMTNR1A | |
| SCHEMBL15942032 | 0.81 | GRM4 (1.00) | GRM4KCNH2HTR2BMTNR1A | |
| SCHEMBL7859091 | 0.79 | GRM4 (1.00) | GRM4KCNH2HTR2BMTNR1A | |
| SCHEMBL18292374 | 0.78 | GRM4 (0.74) | GRM4KCNH2HTR2BMTNR1A | |
| SCHEMBL28199101 | 0.75 | GRM4 (0.85) | GRM4KCNH2HTR2BMTNR1A | |
| SCHEMBL17125410 | 0.74 | MAPT (0.69) | — | |
| SCHEMBL28270083 | 0.74 | ALOX15 (0.52) | — | |
| SCHEMBL100615 | 0.72 | GRM4 (0.62) | GRM4CCNCCDK8 | |
| SCHEMBL17125373 | 0.71 | MAPKAPK2 (0.51) | — | |
| SCHEMBL355762 | 0.70 | GRM4 (0.65) | GRM4KCNH2HTR2BMTNR1ACCNC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150274674-A1 | PYRAZOLE OR TRIAZOLE COMPOUNDS AND THEIR USE FOR THE MANUFACTURE OF A MEDICAMENT FOR TREATING SOMATIC MUTATION-RELATED DISEASES | PTC THERAPEUTICS, INC. (US) | 2015-10-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150274674-A1 | PYRAZOLE OR TRIAZOLE COMPOUNDS AND THEIR USE FOR THE MANUFACTURE OF A MEDICAMENT FOR TREATING SOMATIC MUTATION-RELATED DISEASES | UPF1, RNMT, VHL | GRM4 3933/4885KCNH2 3279/4885HTR2B 4450/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.